Skip to content
Screener

Relmada Therapeutics, Inc. RLMD Return on invested capital

Return on invested capital at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
19.2%+1.3pp
Merck & Co. logo
Merck & Co.MRK
3.7%-18.0pp
Aardvark Therapeutics, Inc. logo
Aardvark Therapeutics, Inc.AARD
-99.8%
CG Oncology logo
CG OncologyCGON
-30.2%+4.7pp
Immunome logo
ImmunomeIMNM
-122.5%-34.9pp
Nuvation Bio logo
Nuvation BioNUVB
-146.8%+87.5pp

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$526.95M+2,719%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024. Open the filing →

Filed
Aug 7, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0001213900-24-066111

FAQ

What is Relmada Therapeutics, Inc.'s return on invested capital?
Relmada Therapeutics, Inc. (RLMD) reported return on invested capital of -49.2% in Q2 2023.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about Relmada Therapeutics, Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude